Difference between revisions of "Vasoactive intestinal peptide"
m |
m |
||
| Line 1: | Line 1: | ||
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | ||
| − | ! | + | ! {infobox header}| '''{{PAGENAME}}''' |
|- | |- | ||
| Substrate peptide name | | Substrate peptide name | ||
| Line 44: | Line 44: | ||
| | | | ||
|- | |- | ||
| − | | | + | | {infobox header} | |
|- | |- | ||
|} | |} | ||
[[Category:Tissue transglutaminase|*]] | [[Category:Tissue transglutaminase|*]] | ||
Latest revision as of 12:01, 10 March 2015
| Vasoactive intestinal peptide | |
|---|---|
| Substrate peptide name | Vasoactive intestinal peptide |
| Synonyms | VIP |
| Determination type | In vitro |
| Source | Homo sapiens |
| Subcellular localization | Extracellular; Secreted |
| Swissprot ID | P01282 |
| Reactive glutamines | Q16 |
| Reactive lysines | K20, K21 |
| Substrate sequence | TRLRKQMAVKKYLNSI |
| Structure | No available crystal structure |
| Surface accessibility | |
| Disorder prediction | IUPred |
| Reference | PMID:12761400 |
| Notes | |
